237 related articles for article (PubMed ID: 33074066)
1. Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study.
Frantellizzi V; Monari F; Mascia M; Costa R; Rubini G; Spanu A; Farcomeni A; Lodi Rizzini E; Cindolo L; Licari M; Lavelli V; Nuvoli S; Ricci M; Dionisi V; Nappi AG; De Vincentis G
Int J Radiat Biol; 2020 Dec; 96(12):1608-1613. PubMed ID: 33074066
[TBL] [Abstract][Full Text] [Related]
2. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
Sartor O; Coleman RE; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Vogelzang NJ; Bruland Ø; Kobina S; Wilhelm S; Xu L; Shan M; Kattan MW; Parker C
Ann Oncol; 2017 May; 28(5):1090-1097. PubMed ID: 28453701
[TBL] [Abstract][Full Text] [Related]
3. Baseline quality of life predicts overall survival in patients with mCRPC treated with
Frantellizzi V; De Feo MS; Di Rocco A; Pontico M; Pani A; Farcomeni A; Cosma L; Lazri J; De Vincentis G
Hell J Nucl Med; 2020; 23(1):12-20. PubMed ID: 32222727
[TBL] [Abstract][Full Text] [Related]
4.
Dizdarevic S; Jessop M; Begley P; Main S; Robinson A
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2264-2273. PubMed ID: 29998419
[TBL] [Abstract][Full Text] [Related]
5. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
[TBL] [Abstract][Full Text] [Related]
6. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with
Frantellizzi V; Farcomeni A; Follacchio GA; Pacilio M; Pellegrini R; Pani R; De Vincentis G
Ann Nucl Med; 2018 Feb; 32(2):142-148. PubMed ID: 29285670
[TBL] [Abstract][Full Text] [Related]
7. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
8. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
Romero-Laorden N; Lorente D; de Velasco G; Lozano R; Herrera B; Puente J; López PP; Medina A; Almagro E; Gonzalez-Billalabeitia E; Villla-Guzman JC; González-Del-Alba A; Borrega P; Laínez N; Fernández-Freire A; Hernández A; Rodriguez-Vida A; Chirivella I; Fernandez-Parra E; López-Campos F; Isabel Pacheco M; Morales-Barrera R; Fernández O; Villatoro R; Luque R; Hernando S; Castellano DC; Castro E; Olmos D
Eur Urol Oncol; 2024 Jun; 7(3):447-455. PubMed ID: 37838555
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen flare induced by
Castello A; Macapinlac HA; Lopci E; Santos EB
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
[TBL] [Abstract][Full Text] [Related]
10. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
12. Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis.
Trieu J; Chang M; Rojas V; Varada N; Cao Y; Anderson M; Vogelzang NJ
Clin Genitourin Cancer; 2022 Oct; 20(5):399-403. PubMed ID: 35680530
[TBL] [Abstract][Full Text] [Related]
13. Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.
van der Doelen MJ; Stockhaus A; Ma Y; Mehra N; Yachnin J; Gerritsen WR; Nilsson S; van Oort IM; Ullén A
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3325-3334. PubMed ID: 33686456
[TBL] [Abstract][Full Text] [Related]
14. Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study.
Hyväkkä A; Kääriäinen OS; Utriainen T; Löyttyniemi E; Mattila K; Reinikainen P; Sormunen J; Jääskeläinen M; Auvinen P; Minn H; Sundvall M
Cancer Med; 2023 Feb; 12(4):4064-4076. PubMed ID: 36156455
[TBL] [Abstract][Full Text] [Related]
15. Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
Zhao H; Howard LE; De Hoedt AM; Terris MK; Amling CL; Kane CJ; Cooperberg MR; Aronson WJ; Klaassen Z; Polascik TJ; Vidal AC; Freedland SJ
Prostate; 2021 May; 81(7):390-397. PubMed ID: 33705584
[TBL] [Abstract][Full Text] [Related]
16. Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region.
Maruzzo M; Basso U; Borsatti E; Evangelista L; Alongi F; Caffo O; Maines F; Galuppo S; De Vivo R; Zustovich F; Palleschi D; Zivi A; Sava T; Sorarù M; Iacovelli R; Nicodemo M; Baier S; Fratino L; Zagonel V
Clin Genitourin Cancer; 2019 Feb; 17(1):e187-e194. PubMed ID: 30448106
[TBL] [Abstract][Full Text] [Related]
17. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT
Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839
[TBL] [Abstract][Full Text] [Related]
18. Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223.
Vidal M; Delgado A; Martinez C; Correa JJ; Durango IC
Int Braz J Urol; 2020; 46(4):599-611. PubMed ID: 32213206
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
Parker C; Finkelstein SE; Michalski JM; O'Sullivan JM; Bruland Ø; Vogelzang NJ; Coleman RE; Nilsson S; Sartor O; Li R; Seger MA; Bottomley D
Eur Urol; 2016 Nov; 70(5):875-883. PubMed ID: 27344296
[TBL] [Abstract][Full Text] [Related]
20. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.
Fosbøl MØ; Petersen PM; Daugaard G; Holm S; Kjaer A; Mortensen J
Ann Nucl Med; 2018 Jan; 32(1):16-21. PubMed ID: 28975586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
